Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBEHAVIORAL PHARMACOLOGY

Human Urocortin 2, a Corticotropin-Releasing Factor (CRF)2 Agonist, and Ovine CRF, a CRF1 Agonist, Differentially Alter Feeding and Motor Activity

Eric P. Zorrilla, Lindsay E. Reinhardt, Glenn R. Valdez, Koki Inoue, Jean E. Rivier, Wylie W. Vale and George F. Koob
Journal of Pharmacology and Experimental Therapeutics September 2004, 310 (3) 1027-1034; DOI: https://doi.org/10.1124/jpet.104.068676
Eric P. Zorrilla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay E. Reinhardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn R. Valdez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koki Inoue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean E. Rivier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wylie W. Vale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George F. Koob
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Two corticotropin-releasing factor (CRF) receptor families have been identified (CRF1 and CRF2). Whereas anxiogenic-like roles for the CRF1 receptor have been identified, behavioral functions of the CRF2 receptor remain obscure. Urocortin 2 (Ucn 2), a CRF-related peptide that selectively binds CRF2 receptors, was recently identified and recognized for its central anorectic properties. The present study tested the hypothesis that the anorexigenic mode of action of Ucn 2 differed from that of ovine CRF (oCRF), a preferential CRF1 receptor agonist. The behavioral effects of intracerebroventricular administration of Ucn 2 were compared with those of oCRF in nondeprived male Wistar rats (n = 102). Ucn 2 reduced 6-h food and water intake at doses that did not induce visceral illness (0.1, 1, and 10 μg), as indicated by kaolin intake. Ucn 2 retained its potent anorectic activity in rats receiving a highly palatable cafeteria diet, preferentially reducing intake of carbohydrate (CHO)-rich items while sparing intake of mixed-fat/CHO items. In contrast to Ucn 2, oCRF (10 μg) suppressed 6-h intake of cafeteria diet-fed rats without regard to macronutrient composition. Rather, oCRF most potently suppressed intake of preferred food items. Whereas oCRF had short-onset motor-activating effects, Ucn 2 had nondose-dependent, delayed-onset motor-suppressing effects. Thus, central infusion of a CRF2 receptor agonist suppressed intake of both bland and palatable diets without inducing behavioral arousal or malaise, and the profile of anorexigenic effects qualitatively differed from those of a CRF1 receptor agonist. The results suggest the existence of distinct forms of CRF1- and CRF2-mediated anorexia.

Footnotes

  • This study was supported by Grants DK26741 and DK64871 from the National Institute of Diabetes and Digestive and Kidney Diseases. G.R.V. was supported by AA05563, an Individual National Research Service Award from the National Institute on Alcohol Abuse and Alcoholism, and is now at the New England Primate Research Center, Harvard Medical School (Southborough, MA).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.104.068676.

  • ABBREVIATIONS: CRF, corticotropin-releasing factor; Ucn 1, urocortin 1; Ucn 2, urocortin 2; Ucn 3, urocortin 3; oCRF, ovine CRF; CTA, conditioned taste aversion; hUcn 2, human Ucn 2; CHO, carbohydrate; MED, minimum effective dose.

    • Received March 18, 2004.
    • Accepted April 28, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 310 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 310, Issue 3
1 Sep 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Urocortin 2, a Corticotropin-Releasing Factor (CRF)2 Agonist, and Ovine CRF, a CRF1 Agonist, Differentially Alter Feeding and Motor Activity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBEHAVIORAL PHARMACOLOGY

Human Urocortin 2, a Corticotropin-Releasing Factor (CRF)2 Agonist, and Ovine CRF, a CRF1 Agonist, Differentially Alter Feeding and Motor Activity

Eric P. Zorrilla, Lindsay E. Reinhardt, Glenn R. Valdez, Koki Inoue, Jean E. Rivier, Wylie W. Vale and George F. Koob
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1027-1034; DOI: https://doi.org/10.1124/jpet.104.068676

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleBEHAVIORAL PHARMACOLOGY

Human Urocortin 2, a Corticotropin-Releasing Factor (CRF)2 Agonist, and Ovine CRF, a CRF1 Agonist, Differentially Alter Feeding and Motor Activity

Eric P. Zorrilla, Lindsay E. Reinhardt, Glenn R. Valdez, Koki Inoue, Jean E. Rivier, Wylie W. Vale and George F. Koob
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1027-1034; DOI: https://doi.org/10.1124/jpet.104.068676
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cromakalim prodrugs are analgesics in chronic pain models
  • Role of Residues S426 and S430 in Cannabinoid Tolerance
  • Running Title: Stimulus effects of nicotine aerosol
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics